Background: The clinical benefits and efficacies of adjuvant therapies for gallbladder cancer (GBC) have not been verified due to insufficient clinical evidence. Methods: Patients with resected nonmetastatic stage II–IV GBC were selected from the Surveillance, Epidemiology, and End Results database and distributed into nonchemotherapy and chemoradiotherapy (NCRT), chemotherapy (CT), and chemoradiotherapy (CRT) groups. Generalized propensity score and inverse probability of treatment weighting (IPTW) were used to reduce the imbalances between groups. Results: A total of 2,689 patients were enrolled, among whom 1,193 (44.4%) were classified as stage II, 1,371 (51.0%) as stage III, and 125 (4.6%) as stage IV GBC. A total of 1,703, 444, and 542 patients were placed in the NCRT, CT, and CRT groups, respectively. After the IPTW, there were no significant differences in overall survival (OS) between the 3 treatment groups (p #x3e; 0.05) in stage II GBC patients. In patients with stage III–IV GBC, the CT group exhibited a superior OS compared to the NCRT group (p #x3c; 0.001). In addition, the CRT group exhibited a superior OS compared to the CT (p #x3c; 0.001) and NCRT (p #x3c; 0.001) groups. For patients with stage III–IV tumors, a nomogram was constructed to predict the survival benefits of adjuvant therapies. Conclusion: Patients with stage II GBC may not benefit from adjuvant therapy, while patients with stage III–IV GBC were shown to benefit from chemotherapy and chemoradiotherapy. Furthermore, chemoradiotherapy exhibited a superior OS. Nevertheless, the results need to be explained in the context of retrospective studies.
Oncol Res Treat

中文翻译：

---

切除的非转移性 II-IV 期胆囊癌的辅助治疗：广义倾向评分分析

背景：由于临床证据不足，胆囊癌（GBC）辅助治疗的临床获益和疗效尚未得到证实。方法：从监测、流行病学和最终结果数据库中选择切除的非转移性 II-IV 期 GBC 患者，并将其分配到非化疗和放化疗 (NCRT)、化疗 (CT) 和放化疗 (CRT) 组。使用广义倾向评分和治疗加权逆概率 (IPTW) 来减少组间的不平衡。结果：共纳入 2,689 名患者，其中 1,193 名（44.4%）为 II 期，1,371 名（51.0%）为 III 期，125 名（4.6%）为 IV 期 GBC。总共有 1,703、444 和 542 名患者分别被置于 NCRT、CT 和 CRT 组。IPTW 后，II 期 GBC 患者的 3 个治疗组之间的总生存期 (OS) 没有显着差异 ( p #x3e; 0.05)。在 III-IV 期 GBC 患者中，CT 组的 OS 优于 NCRT 组（p #x3c； 0.001）。此外，与 CT ( p #x3c; 0.001) 和 NCRT ( p #x3c;0.001) 组。对于 III-IV 期肿瘤患者，构建列线图来预测辅助治疗的生存获益。结论： II 期 GBC 患者可能无法从辅助治疗中获益，而 III-IV 期 GBC 患者显示出从化疗和放化疗中获益。此外，放化疗表现出优越的 OS。然而，结果需要在回顾性研究的背景下进行解释。
肿瘤资源治疗